Furui Co., Ltd. (300049) 2023 Annual Report and 2024 Quarterly Report Review: Rapid growth in the equipment business, net interest rate is expected to gradually increase
Incident: The company released its 2023 annual report and 2024 quarterly report, of which: 1) The company achieved operating income of 1,154 million yuan (YOY +14.4%) in '24 and net profit of 102 million yuan (YO)
Furui Co., Ltd. (300049): The revenue growth rate in the device sector was remarkable in '23, and FIBROSCAN can be expected to be released
Core view: The revenue growth rate of the equipment sector is remarkable. According to the company's annual report for the year 23, the company achieved revenue of 1,154 million yuan (YOY +14.37%) and net profit to mother of 102 million yuan (YOY +3.75%); mainly
Furui Co., Ltd. (300049.SZ) announced first-quarter results. Net profit of 42.7191,000 yuan increased 228.57% year-on-year
According to Zhitong Finance App, Frey Co., Ltd. (300049.SZ) released its report for the first quarter of 2024. During the reporting period, the company achieved operating income of 323 million yuan, an increase of 33.35%; net profit attributable to shareholders of listed companies was 42.791 million yuan, an increase of 228.57% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 41.2912 million yuan, an increase of 126.24% year on year; basic earnings per share were 0.1624 yuan.
Express News | Furui shares: net profit increased 3.75% to 102 million yuan in 2023
Furui Co., Ltd. (300049): FIBRO maintains a high growth rate, equity incentives show confidence
Incident: The company released the 2023 report and the 2024 quarterly report, with 2023 revenue of 1.15 billion yuan (+14.4%) and net profit of 100 million yuan (+3.8%) to mother. 2024Q1 revenue of 320 million yuan (
The Chinese medicine sector fluctuated and rebounded. Ling Rui Pharmaceutical surged 8% to a new high, Tongrentang raised 4% in the short term, and Shouxiangu, Furui shares, and Kunming Pharmaceutical Group had the highest gains.
The Chinese medicine sector fluctuated and rebounded. Ling Rui Pharmaceutical surged 8% to a new high, Tongrentang raised 4% in the short term, and Shouxiangu, Furui shares, and Kunming Pharmaceutical Group had the highest gains.
Furui Co., Ltd. (300049.SZ): As of March 10, 2024, the number of shareholders of the company was 13,361
Gelonghui March 11 | Furui Co., Ltd. (300049.SZ) said on the investor interactive platform that as of March 10, 2024, the number of shareholders of the company was 13,361.
Furui Co., Ltd. (300049): FIBROSCAN maintains rapid growth
Incident: Recently, the company released its 2023 performance report. The company achieved total operating revenue of 1,153 billion yuan, an increase of 14.29% over the same period last year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss 1.
Furui Medical Science's 2023 Attributable Profit Rises 5% on Higher Operating Income
Inner Mongolia Furui Medical Science's (SHE:300049) attributable profit rose 4.81% to 102.6 million yuan in 2023 from 97.9 million yuan in 2022, a Friday filing said. Earnings per share at the Chinese
Frey (300049.SZ) Performance Report: 2023 net profit of 103 million yuan increased 4.81% year-on-year
On February 29, Greenhui Co., Ltd. (300049.SZ) announced its 2023 annual results report. During the reporting period, the company achieved total operating income of 1.153 billion yuan, an increase of 14.29% over the same period of the previous year; net profit attributable to shareholders of listed companies was 103 million yuan, an increase of 4.81% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 111 million yuan, an increase of 11.71% over the same period last year. As of the end of the reporting period, the company's total assets were RMB 275,95.423 million, an increase of 9.39% over the beginning of the period; owned by shareholders of listed companies
Furui Co., Ltd. (300049): FIBROSCAN, the leading non-invasive testing leader for liver disease, can be expected
Core view: The company's performance is progressing steadily. According to the company's 2023 performance report, the company achieved annual revenue of 1,153 billion yuan (YOY +14.3%) and net profit to mother of 103 million yuan (YOY +4.8%)
Guo Jinlong, independent director of Furui Co., Ltd. (300049.SZ), and his nominee Wang Guanyi received a warning letter from the Inner Mongolia Securities Regulatory Bureau
Furui Co., Ltd. (300049.SZ) announced that Guo Jinlong, an independent director of the company, and his nominee, Wang Guanyi, were recently received...
Furui Co., Ltd. (300049.SZ): As of February 20, 2024, the number of shareholders of the company was 14,398
On February 21, Ge Longhui Co., Ltd. (300049.SZ) said on the investor interactive platform that as of February 20, 2024, the number of shareholders of the company was 14,398.
Furui Co., Ltd. (300049.SZ): FibroScan series products can be used to evaluate liver fibrosis, portal hypertension, and liver steatosis
Gelonghui, Feb. 19丨An investor asked Frey Co., Ltd. (300049.SZ) on the investor interactive platform, “Can Frey Fibroscan equipment detect fatty liver cap and fibrosis elasticity in alcoholic fatty liver disease?” The company replied that the company's FibroScan series products can be used to evaluate liver fibrosis, portal hypertension, and liver steatosis.
Furui Co., Ltd. (300049.SZ): As of January 31, 2024, the number of shareholders of the company was 14,641
On February 1, Ge Longhui Co., Ltd. (300049.SZ) said on the investor interactive platform that as of January 31, 2024, the number of shareholders of the company was 14,641.
Frey Shares (300049.SZ): Proposed 2024 Restricted Stock Incentive Plan
Gelonghui, January 31 | Furui Co., Ltd. (300049.SZ) announced the 2024 restricted stock incentive plan (draft). The number of restricted shares to be granted to incentive recipients under this incentive plan is 3 million shares, accounting for about 1.14% of the company's total share capital of 263.5531 million shares when the draft incentive plan was announced. The grant price for restricted shares under this incentive plan is 18.09 yuan/share. The validity period of this incentive plan is not more than 48 months from the date the registration of restricted stock grants is completed until all restricted shares granted by the incentive target are lifted or repurchased and cancelled.
Furui Co., Ltd. (300049.SZ): As of January 20, 2024, the number of shareholders of the company was 13,426
Gelonghui, January 22丨Furui Co., Ltd. (300049.SZ) said on the investor interactive platform that as of January 20, 2024, the number of shareholders of the company was 13,426.
Furui Co., Ltd. (300049.SZ): As of January 10, 2024, the number of shareholders of the company was 13,888
Gelonghui, January 12 | Furui Co., Ltd. (300049.SZ) said on the investor interactive platform that as of January 10, 2024, the number of shareholders of the company was 13,888.
The A-share innovative drug sector rose, and many other stocks such as Furui shares rose more than 4%
Glonghui, January 9 | Frey shares surged 8%. In addition, shares such as Dizhe Pharmaceuticals, Zejing Pharmaceuticals, Yifang Biotech, and Baili Tianheng rose more than 4%. According to the news, according to incomplete statistics from public data, from January 1 to 7, the domestic pharmaceutical industry has officially announced 9 cross-border collaborations involving well-known multinational pharmaceutical companies such as Novartis, AstraZeneca, Boehringer Ingelham, Roche, and Bayer. The cooperation includes various forms such as product licensing, investment, and acquisition, involving popular varieties such as small nucleic acid drugs, antibody conjugation (ADC) drugs, and CAR-T therapy.
Frey shares (300049.SZ): net profit pre-increased by 0% to 30% in 2023
On January 5, Ge Longhui Co., Ltd. (300049.SZ) announced its 2023 annual results forecast. Net profit attributable to shareholders of listed companies during the reporting period was 97.7714 million yuan - 127.2328 million yuan, a change of 0% to 30% over the same period of the previous year; net profit profit after deducting non-recurring profit and loss was 858.714 million yuan - 115.2328 million yuan, a change of -14% to 16% over the same period last year. In 2023, the French holding subsidiary's medical device business continued to expand, achieving an overall net profit of about 180 million yuan to 200 million yuan, which was attributed to listed companies
No Data